Yozma Group

Yozma Group is a Tel Aviv-based venture firm with a foundational role in the history of Israeli venture capital. The original Yozma program in the 1990s seeded the modern Israeli VC industry, and the contemporary firm continues to operate with that long memory, including extensive Asian relationships built up over decades. For AI healthcare founders building life sciences, biotechnology, and advanced medical hardware, Yozma is a strategically distinctive option, particularly when Asian markets are part of the plan.

The relevant thesis covers medical devices and biotech, including AI-enabled imaging, diagnostics, drug discovery support tools, and clinical-stage biotechnology. Pure consumer wellness, lightweight digital health, and SaaS without a deep scientific anchor are not core. The fund tends to favor companies whose technology is genuinely scientific, whose clinical or regulatory path is well thought through, and whose commercial plan considers Asia explicitly rather than as an afterthought.

Check sizes range from $1M to $5M at entry, deployed at Series A and Series B. The fund participates as a co-investor in priced rounds and supports follow-on as companies progress. Geography of investment is principally Israel, with portfolio companies typically operating globally and pursuing the US, Europe, and Asia as commercial markets. The Asian network is the most distinctive aspect of the firm’s offering, including relationships with corporate partners, hospital systems, and capital sources in markets that other Israeli funds cannot easily reach.

The team carries investment, operational, and cross-border experience, with deep familiarity with Asian healthcare ecosystems built over decades. Board engagement focuses on regulatory pathway, commercial partnerships in Asia and elsewhere, and downstream financing strategy. The fund operates with patience characteristic of clinical-stage healthcare investing rather than software timelines.

Founders should approach Yozma when the company is genuinely a life sciences, device, or biotech business with traction, when regulatory work is progressing, and when the strategic plan considers Asian markets credibly. Introductions through Israeli healthtech VCs, hospital collaborators, or cross-border operators are the most efficient path in. The right time to engage is when commercial or clinical signals are emerging, the team has thought carefully about international expansion, and the next round is being structured. Founders pitching consumer wellness, lightweight digital health, or pure SaaS will not find fit. Companies with no credible Asia angle should consider whether a more US-centric fund would serve them better. For founders building deep-tech AI-enabled life sciences and medical hardware companies who want a partner with serious Asian reach, Yozma is one of the more historically credible and strategically useful options in the Israeli ecosystem.